Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Clasificación en acciones #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Precio por acción
$4.36
Capitalización bursátil
$457.32M
Cambio (1 día)
0.69%
Cambio (1 año)
289.29%
País
US
Comercio Relmada Therapeutics, Inc. (RLMD)

Categoría

Ratio P/S de Relmada Therapeutics, Inc. (RLMD)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Relmada Therapeutics, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Relmada Therapeutics, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH